STAT3 and head and neck squamous cell carcinoma: Li and colleagues reported that bortezomib can increase the expression of phosphorylated STAT3 and STAT3 in head and neck squamous cell carcinoma cells, which may contribute to a substantial reduction in its therapeutic efficacy, and co-treatment of bortezomib with a STAT3 inhibitor has been suggested for better anticancer effects [85].